Clinical Trial

Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/ BCMA（QT-019C） in Patients With r/ r Neurological Autoimmune Diseases

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This is an open label, single-site, dose-escalation study in up to 15 participants with relapsed or refractory Neurological Autoimmune Diseases. This study aims to evaluate the safety and efficacy of the treatment with universal CD19/BCMA CAR T-cells（QT-019C）.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-30.
Trial Details
NCT Number NCT07392528
Lead Sponsor Tianjin Huanhu Hospital
Conditions Neuromyelitis Optica Spectrum Disorders, Multiple Sclerosis, Myasthenia Gravis
Enrollment 15 participants
Start Date 2026-03
Primary Completion 2027-06 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2026-02-11